The Epstein-Barr nuclear antigens (EBNA), EBNA-3, -4 and -6, have previously been shown to act as transcriptional regulators, however, this study identifies another function for these proteins, disruption of the G2/M checkpoint. Lymphoblastoid cell lines (LCLs) treated with a G2/M initiating drug azelaic bishydroxamine (ABHA) did not show a G2/M checkpoint response, but rather they display an increase in cell death, a characteristic of sensitivity to the cytotoxic effects of the drug. Cell cycle analysis demonstrated that the individual expression of EBNA-3, -4 or -6 are capable of disrupting the G2/M checkpoint response induced by ABHA resulting in increased toxicity, whereas EBNA-2, and -5 were not. EBNA-3 gene family protein expression also disrupted the G2/M checkpoint initiated in response to the genotoxin etoposide and the S phase inhibitor hydroxyurea. The G2 arrest in response to these drugs were sensitive to caffeine, suggesting that ATM/ATR signalling in these checkpoint responses may be blocked by the EBNA-3 family proteins. The function of EBNA-3, -4 and -6 proteins appears to be more complex than anticipated and these data suggest a role for these proteins in disrupting the host cell cycle machinery.
Introduction

Epstein-Barr virus (EBV) is a herpesvirus that is capable of infecting and transforming resting primary B cells.
Following infection, the B cells become activated, as a result of the expression of about nine EBV latent antigens, and these latently infected lymphoblasts will proliferate indefinitely. These immortalized lymphoblastoid cell lines (LCLs) express a characteristic repertoire of latent antigens (EBNAs 1-6 and LMP-1and -2), which coordinately act to reprogram the cell cycle controls and cause the cells to proliferate indefinitely. EBNA-2 and -5 are expressed within the first 24-32 h following EBV infection, coinciding with the transition from G0 to G1. Between 32 and 48 h postinfection, LMP-1 and -2 are expressed and the levels of EBNA-3, -4 and -6 begin to rise, corresponding to the cells moving into S phase and progression through the cell cycle.
The cell division cycle is driven by the sequential activation of a series of cyclin-dependent kinases (cdk/s). The timing of activation of the different cdk isoforms determines the order of occurrence of the major cell cycle transitions: entry into G1 phase, onset of DNA replication and entry into mitosis (Morgan, 1995) . An intricate network of redundant control mechanisms exists to establish the precise timing and sequence of activation of the various cdk isoforms. These regulatory mechanisms, known as checkpoints, ensure that progression through key cell cycle phase transitions occurs only after successful completion of the preceding phase by regulating the cdk/cyclin activities responsible for normal phase cell cycle progression (Elledge, 1996) . Disruption of host cell checkpoint mechanisms is common in cancer and for transforming DNA viruses such as SV40, adenovirus and papilloma virus. The common cellular targets of viral gene products are host cell tumour suppressor gene products such as p53 and Rb, which also have important checkpoint functions. Unlike other DNA viruses, which inactivate p53 and pRB by direct interaction, EBV appears to modulate indirectly the activities of pRB by interaction with the signalling pathways that intersect with it (Cannell et al., 1996) , while there is no evidence that EBV interferes with p53 function (Sinclair et al., 1998) . However, EBV is still capable of very efficiently transforming resting B lymphocytes and inducing activation and continuous proliferation of the resting B cells suggesting that the virus has devised other ways of manipulating the host cell cycle control mechanisms.
The use of recombinant EB viruses and in vitro assays have been used to determine the latent genes responsible for interfering with the host cell cycle machinery, and to date most of this work has focused on G0/G1 transition and the G1 restriction point (reviewed in Sinclair et al., 1998) . The combination of EBNA-2 and -5 leads to the upregulation of cyclin D2, a necessary step towards driving resting B cells from G0 to G1 (Sinclair et al., 1994) . The G1 restriction point is thought to be facilitated by EBNA-6 via the disruption of the cyclin/ CDK-pRB-E2F pathway (Parker et al., 1996) . While the mechanism for G2/M progression in EBV transformed cells has not been characterized, studies have suggested that EBNA-6 may also facilitate this stage of the cell cycle. In NIH3T3 fibroblasts arrested by serum depletion, expression of EBNA-6 maintained cell proliferation and induced nuclear division in the absence of cytokinesis. In addition, the study showed that EBNA-6 can abrogate the mitotic spindle checkpoint that was activated by a microtubule destabilizing drug (Parker et al., 2000) . More recently, Wade and Allday (2000) have demonstrated that EBV is capable of suppressing a G2/M checkpoint activated by genotoxic drugs. Interestingly, expression of LMP-1 in B cell lines has been shown to produce a G2/M block in cells (Floettmann et al., 1996) .
EBNA-3 family of proteins (EBNA-3, -4 and -6, also known as EBNA-3a,-3b, and-3c) are nuclear phosphoproteins with molecular weights ranging from 130 to 160 kDA and are thought to act as transcriptional regulators. Only EBNA-3 and -6 have been shown to be essential for B-cell transformation. A number of functional domains have been characterized for the proteins, including transactivation domains repression domains, and nuclear localization domains; however, their precise functional role has not been elucidated. EBNA-3, -4 and -6 are capable of binding to RBP, through a conserved region (Robertson et al., 1996) , while EBNA-3 and -6 can bind to the ATPase/Helicase DP103 (Grundhoff et al., 1999) . EBNA-6 appears to also have repressor functions potentially mediated via its interaction with a histone deacetylase (Radkov et al., 1999) . In addition, studies have shown that EBNA-6 is an immortalizing oncogene capable of cooperating with (Ha)-ras in cotransformation assays and is capable of overriding Rb-mediated pathways (Parker et al., 1996) .
We have recently reported that the histone deacetylase inhibitor ABHA is cytotoxic to a number of LCL lines, although normal B cells appeared to be resistant to killing by this drug (Sculley et al., 2002) . Resistance to the cytotoxic action of ABHA is the consequence of an intact G2/M checkpoint, but a high proportion of immortalized and tumour cell lines are defective for this checkpoint arrest and are consequently sensitive to killing by ABHA (Qiu et al., 2000; Burgess et al., 2001) . The sensitivity of all the EBV immortalised LCLs tested suggests that EBV may disrupt the G2/M checkpoint response to ABHA, possibly in a similar manner to the reported disruption of the G2/M checkpoint response to other agents (Wade and Allday, 2000) . In order to define the mechanism by which EBV compromises cell cycle checkpoints, we have examined the ability of the EBV latent antigens EBNAs 1-6 to disrupt the ABHA-sensitive G2/M checkpoint response. This study identifies a new function for the EBNA-3 gene family proteins; disruption of the G2/M checkpoint that is induced by a range of agents, including the genotoxin etoposide and the DNA synthesis inhibitor hydroxyurea.
Results
EBV is capable of disrupting the G2/M checkpoint arrest induced by ABHA
A panel of 12 EBV immortalized LCLs and the EBVnegative Burkitts' lymphoma (BL) B cell line DG75 were treated with 100 mg/ml ABHA for 24 and 48 h, and their cell cycle distribution patterns were determined by flow cytometry (Figure 1 ). Three representative LCL lines are shown. Untreated control cells showed a normal log phase growth cell cycle distribution pattern. Following ABHA treatment, all the LCLs showed a decreased percentage of cells in the S and G2/M phases, and an increase in the o2n population representing dead and dying cells (Qiu et al., 2000; Burgess et al., 2001) . This distribution pattern was consistently observed in all LCLs investigated. By comparison, the EBV-negative DG75 cells demonstrated an accumulation of cells with 4n DNA, indicative of a G2/M arrest, and were resistant to the cytotoxic effects of the drug, with only 9% of subdiploid cells observed after 48 h drug treatment (Figure 1 ). These results suggest that EBV immortalization of B cells increased their sensitivity to the cytotoxic actions of ABHA by disrupting the G2/M checkpoint following ABHA treatment, as reported with other tumour cell lines (Qiu et al., 2000) .
EBNA-3, -4 and -6 are capable of disrupting the G2/M checkpoint induced by the histone deacetylase inhibitor ABHA Given that EBV was capable of disrupting the G2/M checkpoint response to ABHA, it was important to establish which of the EBV latent proteins was responsible for this effect. As the G2/M checkpoint response was intact in DG75 cells, they provided the ideal cell line to evaluate the effects of the EBV latent proteins. A panel of DG75 cells tranfected with the empty vector alone or the vector expressing individual EBNA-2, -3, -4, -5, -6 were selected, then treated with 100 mg/ml ABHA for 24 and 48 h, and their cell-cycle distributions determined by flow cytometry (Figure 2a) . Expression of the individual EBNA genes did not affect the normal cell cycle distribution. Treatment of DG75-EBO (empty vector control cells), DG75-EBNA-2 and DG75-EBNA-5 cells with 100 mg/ml ABHA for 24 or 48 h produced the expected G2/M arrest in these cell lines and little cell death. In contrast, treatment of DG75 cells expressing the individual EBNA-3 family proteins failed to arrest in G2/M and showed an increase in the percentage of cells with o2n DNA content. This response is similar to the effects observed in LCLs expressing the full set of the EBV latent genes ( Figure 1 ) and was identical to the response in other tumour and transformed cell lines that were defective for the ABHAsensitive G2/M checkpoint response (Qiu et al., 2000) . The increased cytotoxicity of ABHA was further demonstrated by assaying the proliferation and viability of DG75, EBO control, and EBNA-3 and -4 transfectants. At high doses of ABHA, both DG75 and EBO transfected controls showed a proliferative arrested, confirming that the G2/M accumulation observed by FACS was indeed a cell cycle arrest (Figure 2b ). Cells expressing EBNA-3 or -4 lost viability at high doses of ABHA, in agreement with the increase in subdiploid cells observed by FACS (Figure 2a ). The expression of the EBNA-2, -3, -4, -5 and -6 proteins in the transected DG75 cells was confirmed by Western blotting (Figure 2c ). These results suggest that EBNA-3, -4 and -6 were all capable of disrupting the G2/M checkpoint response induced by ABHA, thereby increasing the sensitivity of cells expressing EBNA-3 family proteins to the cytotoxic effects of ABHA.
EBNA-3, -4 and -6 are capable of disrupting the G2/M checkpoint induced by genotoxic drugs In attempting to synchronize the DG75 cells expressing the individual EBNA-3 family proteins, to examine the loss of the ABHA-sensitive G2/M checkpoint arrest, we noted that these cells failed to stably arrest in S phase after treatment with the DNA inhibitor hydroxyurea. This suggested that the EBNA-3 gene family proteins were capable of disrupting not only the ABHA-sensitive G2/M checkpoint, but were possibly capable of disrupting the checkpoints induced by other agents. The cell cycle responses of control and EBNA-3 family expressing DG75 cell lines to sublethal doses of etoposide, which activates a DNA damage checkpoint in G2 phase (Lock, 1992) , and hydroxyurea (HU), which initiates a replication checkpoint by blocking S phase progression, were evaluated. DG75 EBO (vector control cells) and DG75 cells transfected with the individual EBNA-2, -3, -4, -5 or -6 genes were treated with 1 mM etoposide for 24 and 48 h (Figure 3a) . After 24 h treatment, all cell lines displayed an accumulation of cells with 4n DNA content, suggestive of a G2/M arrest, also displayed a significant increase in the proportion of subdiploid cells compared with the control, EBNAs-2 and -5 expressing cells. The G2/M arrest appeared to be stable after 48 h etoposide treatment in the DG75 EBO, DG75 EBNA-2 and DG75 EBNA-5, with 470% of cells in each population in the 4n compartment, and little cell death indicated by the low proportion of subdiploid cells. By contrast, the proportion of cells with 4n DNA was reduced to o 45% in EBNA-3, -4, and -6 expressing cells after 48 h treatment, with a commensurate increase in the subdiploid population (o2n). There was also an increase in the proportion of S phase cells in these cell lines. The decrease in cells with 4n DNA content and increase in the subdiploid and S phase compartments in the cell lines expressing EBNA-3, -4, or -6, suggested that the cells failed to arrest at the G2/M checkpoint after etoposide treatment. The remaining cells with 4n DNA content at 48 h were likely to be cells that have failed cytokinesis due to the drug inhibiting topoisomerase II, which is necessary for sister chromatid separation.
To evaluate the effect of the EBNA-3 family proteins on the S phase replication checkpoint, DG75 EBO, DG75 EBNA-2, DG75-EBNA-3, DG75-EBNA-4, DG75-EBNA-5 and DG75 EBNA-6 cells were treated with HU for 24 and 48 h and then their cell cycle distribution patterns determined by flow cytometry. The cell cycle distributions for these cell lines are shown ( Figure 3b ). Treatment of DG75-EBO, EBNA-2 and -5 cells with 2 mM HU for 24 and 48 h showed an increase in the percentage of cells in G1 and loss of G2/M phase In contrast after treatment with 2 mM HU for 48 h, DG75 cells expressing EBNA-3, -4 or -6 showed a dramatic increase in the o2n population and a commensurate reduction in the G1 and S phase populations. These results suggested that expression of EBNA-3 family proteins disrupted the S phase replication checkpoint and G2/M DNA damage checkpoint responses.
Biochemical characterization of the G2/M checkpoint arrest
To further assess these checkpoint responses, biochemical analysis of markers of the G2/M cell cycle checkpoint were analysed. A common feature of each of the agents used in this study is that they each initiate a G2/M phase checkpoint arrest. Both ABHA and etoposide induce a G2/M arrest, indicated by the G2/M accumulation observed in DG75 cells (Figures 2 and 3 ) (Lock, 1992; Qiu et al., 2000) , and the S phase replication checkpoint initiated by HU treatment also blocks the cell cycle machinery that controls progression into mitosis (Enoch and Nurse, 1990; Kumagai and Dunphy, 1991) . The ultimate target of all of these checkpoints is a block in the activation of cyclin B/cdc2, the critical regulator of mitosis, detected as an accumulation of the inactive Tyr15 phosphorylated form of the cdc2/cyclin B complex. Therefore, the abrogation of the checkpoint response to each of these agents by the EBNA-3 family proteins should result in disruption of the mechanism blocking cdc2/cyclin B activation and lack of accumulation of this inactive complex. To investigate this, the levels of cyclin B1 and the inactive Tyr15 phosphorylated form of cdc2 were analysed by immunoblotting from lysates of equal numbers of either untreated control cells or ABHA-, etoposide-or HUtreated DG75 EBNA-3 family expressing cells. Results from the EBNA-3 expressing cells are shown ( Figure 4a and b), while the DG75 cells expressing EBNA-4 and EBNA-6 showed similar results. The levels of cyclin B1 were elevated in DG75-EBO control cells after etoposide (4.4-fold) and small increases in cyclin B1 levels were also detected with ABHA (2.0-fold) and HU (2.2-fold) treatment relative to untreated control cells. The relatively low level of cyclin B1 in the G2 arrested, ABHA-treated cells was a consequence of cyclin B1 downregulation during the arrest with this drug (Qiu et al., 2000) . The small cyclin B1 accumulation in the HU-treated cells was due to the arrest of late S phase cells in which cyclin B1 normally starts accumulating Equal cell numbers of each cell line were harvested and total cell lysates prepared. Following electrophoresis and Western transfer, the membranes were probed for EBNA-1, -2, -3, -4 and -6 (lanes 1-7: MCr sera) and EBNA-5 (lanes 8-10; anti-E5 (Pines and Hunt, 1987) . By contrast, there was little change in the levels of cyclin B1 in the EBNA-3 expressing cells. The accumulation of cyclin B1 in the etoposide-treated cells was likely to be a consequence of slowed progression through mitosis due to the inability of sister chromatid to separate properly, a result of topoisomerase II inhibition by etoposide. Similar changes in the levels of the Tyr15 phosphorylated form of cdc2 were observed, where DG75-EBO control cells showed elevated levels after HU (4.2-fold), etoposide (9.6-fold) and ABHA (2.1-fold) treatment, corresponding to the accumulation of cyclin B1 observed. This was expected as Tyr15 phosphorylation of cdc2 is dependent on cyclin B association (Morgan, 1995) . Again, EBNA-3 expressing cells showed no change. Elevated levels of cyclin B1 and phosphorylated cdc2 are consistent with a G2/M arrest by each agent in DG75 EBO control cell lines and the lack of this accumulation in EBNA-3 family expressing cell lines confirms the absence of checkpoint arrest detected by flow cytometry. The lack of accumulation of Tyr15 phosphorylated cdc2 in the Disruption of the G2/M checkpoint following induction of the EBNA-3 gene family proteins
To determine whether the apparent disruption of the G2/M checkpoint was an immediate consequence of induction of the EBNA-3 family proteins or an adaptive response to their expression, a DG75 cell line was established in which the EBNA-3 family proteins, EBNA-3, -4 and -6, were under the control of a cadmium-inducible promoter. DG75 pMEP4-E346 cells or empty vector control DG75 pMEP4 cells were incubated with cadmium for 16 h and then either 100 mg/ml ABHA or 1 mM etoposide was added to cells. HU treatment was not assessed as this did not provide as easily accessible G2/M population. Cells were harvested after 24 h and analysed for their cell cycle distribution pattern by FACScan and Western blotted to assay EBNA-3,-4 or -6 expression levels ( Figure 5 ). Following etoposide treatment of DG75 vector control or DG75 pMEP4-E346 cells, the percentage of cells in the G2/M phase of the cell cycle was increased (83.577.9%) compared to untreated cells (16.474.1%). The prior addition of cadmium to these cells lead to a dramatic decrease in the percentage of cells in the G2/M phase following etoposide treatment of DG75 pMEP4-E346 cells (39.376.1%), whereas DG75 pMEP4 vector control cells showed only a small reduction in G2/M content. The reduction in the percentage of cells in the G2/M phase following cadmium treatment corresponded to an increase in the expression of the EBNA-3, -4 and -6. ABHA treatment of DG75 pMEP4 vector controls leads to an increase in the percentage of cells in the G2/M phase of the cell cycle (68%), which was not significantly effected by prior cadmium treatment (64%). Interestingly, ABHA treatment of DG75 pMEP4 E346 cells resulted in relatively reduced accumulation of cells in G2/M phase (50.7710.1), which was only marginally decreased by prior cadmium induction (44.078.5%). This apparent lack of effect of cadmium-induced expression of EBNA-3, -4 and -6 was due to the ability of ABHA itself to induce expression of the EBNA-3 family proteins from the metallothionine promoter (Figure 5b ), most likely a consequence of changes in acetylation of the chromatin histones in the pMEP4 metallothione promoter induced by the histone deacetylse inhibitor ABHA (Richon et al., 1998) . The percentage of cells in the G2/M phase in untreated DG75 vector control and DG75 pMEP4 E346 cells was not affected by cadmium treatment.
The reduction in the proportion of cells accumulating in the G2/M compartment after EBNA-3, -4 and -6 induction suggested that these cells were failing to arrest in G2 phase and were proceeding normally through mitosis. This was assessed in similar experiments to that in Figure 5 . After 16 h cadmium induction, cells were treated with 100 mg/ml ABHA, 1 mM etoposide or 2 mM HU, then harvested 16 h later, and the proportion of cells staining with the mitosis-specific antibody MPM-2 (Westendorf et al., 1994) was also quantitated using FACS. Both pMEP4 and pMEP E346 expressing cells contained approximately 2% MPM-2 staining cells (Figure 6a and b, only the 16 h data shown). Interestingly, ABHA treatment resulted in a twofold increase in the MPM-2 staining in pMEP4 expressing cells, suggesting that in addition to the G2 arrest induced by this drug, ABHA treatment also caused a delay in mitosis. This may be the result of the aberrant mitosis observed previously in ABHA-treated cells being arrested by the mitotic spindle checkpoint (Qiu et al., 2000) . EBNA-3, -4, -6 expression increased the proportion of MPM-2 staining 42-fold compared with pMEP4 controls, indicating that cells were not being arrested in G2 phase but proceeding into mitosis where they were delayed due to effect of ABHA on mitosis (Qiu et al., 2000) . Both etoposide and HU treatment resulted in a decrease in the proportions of MPM-2 staining pMEP4 control cells to less than 30% of the untreated controls indicating that these agents imposed a premitotic arrest. Induction of EBNA-3, -4, -6 expression rescued the loss of MPM-2 staining, confirming that the cells were not arrested by treatment with these drugs but proceeded through G2 into mitosis. Together, the increased proportion of subdiploid cells, the failure to accumulate the inactive cdc2/cyclin b1 complex, and the ability of short-term expression of the EBNA-3 family of proteins to reduce the G2/M accumulation and retain normal entry into mitosis demonstrate that induction of EBNA-3, -4 and -6 expression is capable of disrupting the G2/M checkpoint induced by ABHA, etoposide and HU treatment.
ATM/ATR signalling plays a role in the G2 arrest following HU, ABHA and etoposide treatment
The ATM (ataxia telangiectasis mutated)/ATR (ATMRad3-related) DNA damage response pathway is a network of interacting pathways that act at the G2 phase of the cell cycle to block G2/M progression by ultimately blocking the activation of cdc2/cyclin B (Zhou and . The ability of the EBNA-3 family proteins to disrupt the G2/M checkpoint response to a range of different agents that produce very different cellular effects suggested that the EBNAs were targeting a common pathway used in the response to all these agents. The ATM/ATR dependent signalling appeared the most likely candidate as it is involved in the G2/M checkpoint responses to etoposide and HU (Connell et al., 2000) , although its involvement in the G2/M arrest following ABHA treatment had not been established. This was examined using the known sensitivity of both ATM and ATR to inhibition by caffeine (Blasina et al., 1999) . DG75 cells were synchronized using an overnight arrest in 2 mM HU, then released with four washes of fresh, prewarmed media. Cells traversed through S and G2 phases into mitosis by 12-14 h after release with approximately 50% synchrony. Synchronized DG75 cells were then treated with ABHA, etoposide or HU, then half of each culture treated with 5 mM caffeine as the cells transited through G2 phase and all the cells harvested at 14 h as the controls transited through mitosis. The cells were analysed for cdc2/cyclin B1 activity as a direct measure of the G2/M checkpoint function and were stained for MPM-2 as an independent marker of entry into mitosis. Caffeine rescued the reduction of cdc2/cyclin B1 activity and MPM-2 staining normally observed after treatment with each of the drugs, indicating the involvement of ATM/ATR in the ABHA G2 arrest response as well as those in response to etoposide and HU treatment (Figure 7) . Thus, ATM/ ATR signalling is used in response to all these drugs, suggesting that this signalling pathway is a likely target of the EBNA-3 family proteins.
Coimmunoprecipitation of EBNA-3 and chk2
These data suggest that the EBNA-3 gene family proteins are disrupting the function of a single gene or gene product that is common to each of the checkpoint responses. A candidate is the checkpoint kinase chk2/ cds1. This kinase is activated in response to DNA damage and replicative arrest in both yeast and humans and is capable of phosphorylating cdc25C, which leads to inhibition of its ability to activate cdc2/cyclin B complexes necessary for G2/M transition (Matsuoka et al., 1998; Zeng et al., 1998; Blasina et al., 1999; Brondello et al., 1999) . To determine if there was an association between EBNA-3 family proteins and chk2, co-immunoprecipitations were performed in EBV-transformed B cell lines, LCLs, expressing all the EBV latent proteins (Figure 8a ). Cell lysates were prepared from QIMR/NB B95.8 LCL, QIMR/CS B95.8 LCL, DG75 and DG75 EBO-EBNA-2 cells in RIPA buffer and antichk2 antibodies were used for the immunoprecipitations. Following electrophoresis and transfer of the immunoprecipitates, the membrane was probed with MCr sera to detect EBNA-3, -4 or -6 or anti-chk2 antibody to detect chk2 to ensure that the immunoprecipitations were successful. Chk2 was successfully precipitated from all cell lines in the presence of Figure 6 EBNA-3 family expression overcomes drug-induced G2 arrest. DG75 cells expressing either the empty vector pMEP4 or pMEP4-E346 were induced with cadmium and then treated with drugs as in Figure 5 , then harvested at 16 h after drug treatment. Cells were stained for the mitosis-specific phosphoepitope MPM-2 and propidum iodide for DNA content, then the staining quantitated using FACS. 4) ; however, EBNA-4 and -6 were not observed. Again, only small amounts of EBNA-3 are co-immunoprecipitated with chk2, as evidenced by the amount of EBNA-3 seen in lanes 3 and 4 and that in the total lysate, which corresponds to 5 Â 10 5 cells (lane 5). To demonstrate the specificity of the co-immunoprecipitations, cell lysates were prepared from CS B95.8 and MM B95.8 LCLs and immunoprecipitations were performed using anti-chk2, an irrelevant antibody (anti-SOS), or protein A alone (no antibody) (Figure 8b ). EBNA-3 was co-immunoprecipitated with chk2 from the LCLs, while control coprecipitations did not show evidence of EBNA-3 or chk2 proteins. While the majority of chk2 is immunoprecipitated from the cell lysate, only a small percentage of EBNA-3 is co-precipitated (lane 4 has lysate from 5 Â 10 5 cells, whereas the co-immunoprecipitations were performed on 5 Â 10 6 cells). To confirm that chk2 was interacting with EBNA-3, rather than EBNA-4 or -6, immunoprecipitations were performed using antibodies to chk2 and EBNA-3 from the LCL CSB95.8 and this showed that both antibodies immunoprecipitated the EBNA-3 protein ( Figure 8c ). As well immunoprecipitations, using anti-chk2 antibody, were performed from DG75 cells transfected with either a plasmid expressing EBNA-3 or empty vector (Figure 8d) , which demonstrated that EBNA-3 was immunoprecipitated with the anti-chk2 antibody from DG75 cells expressing EBNA-3 but not from the vector control transfectant. These results showed that chk2 is capable of specifically 3) and MM B95.8 (lanes 5-7), using either anti-chk2 antibody (anti-chk2), an irrelevant antibody control (anti-sos) or protein A alone (À). The co-ips were separated by electrophoresis, transferred to membranes and then probed with anti-chk2 antibodies (upper panel) or MCr (lower panel) to detect the EBNA-3 family proteins. The location of chk2 and EBNA-3 are shown by the arrows. Lane 4 contains total cell lysate prepared from 5 Â 10 5 MM B95.8 LCL. (c) Immunoprecipitations performed on the LCL CS B95.8 using either anti-chk2 antibody (anti-chk2), anti-EBNA-3 antibody or protein A alone (no antibody). The coips were separated by electrophoresis, transferred to membranes and then probed with MCr serum to detect the EBNA-3 protein.
(d) Immunoprecipitations performed on DG75 cells transfected with either EBO-EBNA-3 or an empty EBO vector using anti-chk2 antibody. The co-ips were separated by electrophoresis, transferred to membranes and then probed with MCr serum to detect the EBNA-3 protein. The location of EBNA-3 is shown by the arrow and the position of molecular weight markers is shown EBNA-3 disrupts G2/M checkpoint KG Krauer et al binding to EBNA-3, but not EBNA-4 or -6, in LCLs. These results indicate that EBNA-3 associates with chk2 in LCLs expressing the full set of EBV latent antigens, and suggest that this interaction could be responsible for the G2/M checkpoint disruption.
Discussion
Transformation by EBV requires the coordinate and timely expression of a number of latent genes that also act to maintain the immortalized state. The functions of the individual genes required during these events has been the focus of research for many years; however, the roles of the EBNA-3 gene family proteins has remained elusive. Evidence has been presented to suggest that the proteins act as transcriptional regulators, especially given their ability to bind and sequester the DNAbinding protein RBP (Krauer et al., 1996; Zhao et al., 1996) , activate reporter constructs (Marshall and Sample, 1995) and modulate gene expression (Wang et al., 1990; Silins and Sculley, 1994) , and EBNA-3 and -6 are essential for viral transformation (Tomkinson et al., 1993) .
Analysis of the effect of ABHA on LCLs demonstrated that they did not arrest at the G2 cell cycle checkpoint but instead underwent cell death, a response similar to that previously seen with tumour and transformed cell lines that have a dysfunctional checkpoint (Qiu et al., 2000) . ABHA acts by inducing a G2/M arrest in cells that have a functional checkpoint response, whereas in cells that have a defective checkpoint, a G2/M arrest is not seen and cells die as a consequence of passing through G2/M. This suggested that LCLs must also have a dysfunctional G2/M checkpoint, as has also previously been shown by Wade and Allday (2000) , and suggested that one of the EBVencoded proteins was responsible for this effect. Investigation of the EBV latent genes (EBNA-2, -3, -4, -5 and -6) revealed that the EBNA-3 gene family proteins were responsible for this observed checkpoint disruption imposed in response to treatment with ABHA, etoposide and HU. This is supported by the biochemical analysis of a marker of G2 arrest, accumulation of the inactive Tyr15 phosphorylated cdc2/cyclinB1 complex and the mitotic marker MPM2.
Here, we have shown that expression of the EBNA-3 family proteins was sufficient to bypass the G2/M checkpoint arrest imposed in response to a range of different agents. These agents affect very different cellular processes, from blocking replication and disrupting chromatin structure, to causing DNA strand breaks. That the checkpoint responses to each of these agents should be disrupted suggests that an effector common to all the checkpoint response pathways is targeted by the EBNA-3 proteins. We have shown that the G2/M checkpoint response to all of these agents is sensitive to inhibition by caffeine, implicating ATM/ ATR. One of the checkpoint kinases downstream of ATM/ATR that is activated in response to both etoposide and HU is chk2/cds1 (Matsuoka et al., 1998; Blasina et al., 1999; Chaturvedi et al., 1999) . Chk2 is also activated in response to other agents that initiate G2 phase arrests, such as the plant isoflavone genistein (Darbon et al., 2000) . The G2 phase DNA damage checkpoint is defective in chk2 À/À embryonic stem cells (Hirao et al., 2000) , supporting a role for chk2 in the G2 checkpoint response. The fission yeast orthologue, cds1, is required for the G2 checkpoint arrest in response to both incomplete replication and DNA damage incurred during S phase (Lindsay et al., 1998; Brondello et al., 1999) . We have examined the ATM-dependent phosphorylation of chk2 Thr69; however, the high level of this phosphorylation even in untreated DG75 cells precluded the detection of small changes in this event after drug treatment (unpublished observations). Further studies are required to assign definitively a role for chk2 in the G2 arrest response to each of the agents used in this study, but it is a good candidate.
The observed physical interaction between EBNA-3 and chk2 in EBV-infected LCLs suggest that EBNA-3 disrupts the G2 checkpoint response by blocking normal chk2 function. This is supported by the finding that disruption of the G2 checkpoint responses is an immediate effect of EBNA-3 family protein expression rather than an adaptive response to longer term expression. In vivo, the EBNA-3 family proteins (Petti et al., 1990) and chk2 are located in the nucleus (Chehab et al., 2000) , facilitating this interaction. While only small amounts of EBNA-3 are co-precipitated with chk2, a number of reasons could account for this finding; (1) both chk2 and EBNA-3 have other binding partners, (2) the interaction may be cell cycle regulated and/or (3) the bulk of the EBNA proteins are contained within the insoluble fraction after RIPA buffer extraction (Cludts and Farrell, 1998) , leading to only small amounts available for interaction and co-immunoprecipitation studies. EBNA-3 binding to chk2 may destabilize the protein, increasing its turnover, similar to the effect of HPV18 E6 protein that directly binds and destabilizes p53, thereby mimicking the role of MDM2 in regulating p53 levels and function (Villa, 1997) . Alternatively, the mechanism of action could be similar to that reported for HPV18 E7 protein that binds to the pocket region of the Rb-related proteins, thereby blocking their ability to sequester the E2F family proteins (Goodwin and DiMaio, 2000) , although E7 binding has also been reported to destabilize the Rbrelated proteins (Berezutskaya et al., 1997) . Either of these two mechanisms could also account for the lower level of chk2 protein observed in the DG75 cell lines expressing the individual EBNA-3 proteins (unpublished observation) . While the EBNA-3 family proteins have demonstrated transcriptional effects, the contribution of any transcriptional effects of EBNA-3 family protein on the chk2 activity and expression is not clear.
Chk2 has also been implicated in the regulation of p53 function and is capable of phosphorylating Ser20 on p53, which increases p53 stability after DNA damage (Chehab et al., 2000; Hirao et al., 2000) . However, p53 function is not affected by EBV transformation suggest-ing either that this chk2 function is not disrupted by EBNA-3 association, or that other kinases can complement this loss of function. Interestingly, the checkpoint kinase chk1 has been identified as a p53 ser20 kinase (Shieh et al., 2000) and it may perform this role in vivo to complement loss of chk2 function. Clearly, the mechanism by which the EBNA-3 family proteins disrupt chk2 function, and the consequences of this disruption requires further detailed study.
To enable EBV to drive resting B cells into proliferating lymphoblasts would require the expression of viral proteins capable of manipulating the host cell cycle machinery. The initial G0-G1 transition is thought to be controlled by the expression of EBNA-2 and -5, through their ability to upregulate the expression of the G1 cyclin D2 (Sinclair et al., 1994) . Progression into S phase is preceded by the expression of LMP-1 and -2 and EBNA-3, -4 and -6. Earlier studies have suggested that expression of LMP-1 in B cell lines can lead to cytostatic effects, impose a block in cells in the G2/ M phase of the cell cycle (Floettmann et al., 1996) and can lead to reduced cell growth (Kaykas and Sugden, 2000) . To overcome these effects, EBV would need to encode a protein/proteins capable of opposing these effects to maintain the immortalized state of the cells. The results presented here would suggest that this could be the function of the EBNA-3 gene family proteins. These proteins could bind to and inactivate chk2 thereby inactivating the checkpoint response, and therefore prevent the G2/M cell cycle accumulation/cytostasis from occurring. Studies are currently underway to dissect the signalling components involved in these pathways and investigate the domains of EBNA-3 involved in this interaction.
This study has identified a new role for the EBNA-3 gene family proteins, disruption of the DNA damage and replication G2/M checkpoint. These findings are in agreement with a recent report by Parker et al. (2000) showing that EBNA-6 can disrupt multiple cell cycle checkpoints, and a report by Wade and Allday (2000) demonstrating that EBV suppresses a G2/M checkpoint activated by genotoxic agents. In addition, this study extends the work from these previous studies and identifies the mechanism for the observed G2/M checkpoint disruption.
Materials and methods
Reagents
ABHA was synthesized by Matthew P Glen (Centre for Drug Design and Development, University of Queensland). Etoposide, HU and cadmium chloride (CdCl 2 ) were purchased from Sigma Chemicals. The following antibodies were used in the study: anti-cyclinB1 (Gabrielli et al., 1996) , anti-PY15 to detect phosphorylated cdc2 (Cell Signalling Technology), anti-PCNA, anti-EBNA-2 and anti-MPM-2 (DAKO), anti-SOS (Santa-Cruz Biotechnology Inc.), anti-EBNA-5 (supplied by Martin Rowe, University of Wales) and the anti-EBNA6 clones A10 and D8 (Maunders et al., 1994) .
Cell line maintenance
The lymphoblastoid cell lines were maintained in RPMI 1640 supplemented with 10% fetal calf serum, benzylpenicillin (0.7 mg/ml) and streptomycin (1 mg/ml) at 371C in 5% CO 2 atmosphere. The following cell lines were used during the study: EBV-negative BL DG75 (Ben Bassat et al., 1977) , DG75 cells transfected with EBNA-3, -4, -6, and control vector EBO (Kienzle et al., 1996b) , and the LCLs: QIMR-DJM/Ag876 (produced by infection of human B lymphocytes from donor DJM with the virus strain Ag876), QIMR-NB/ B95.8, QIMR-MW/B95.8 and QIMR-LC/B95.8 (produced by infection of human B lymphocytes from donor NB, MW and LC with the virus strain B95.8), and QIMR-KE/WIL (produced by infection of human B lymphocytes from donor KE with the virus strain WIL). DG75 cells were synchronized using an overnight arrest in 2 mM HU, then released with four washes of fresh, prewarmed media. Cells traversed through S and G2 phases into mitosis by 12-14 h after release with approximately 50% synchrony.
MTT assay for viability and proliferation
Cells in log phase growth were seeded into 96-well plates at a density of 2-5 Â 10 3 on the day before the addition of ABHA. Cell proliferation was measured using 3-[4,5-dimthylthiazol2yl]-2,5-diphenyltetrazolium bromide (MTT), which measures mitochondrial activity of viable cells. MTT was added to the culture medium at a final concentration of 0.5 mg/ml, and the plated cells were incubated for 4 h at 371C. The insoluble formazan product was then precipitated by centrifuging the plates, removing the supernatant and redissolving the formazan crystals in 100 ml of DMSO. Absorbance at 570 nm was measured using a Bio-Rad (Hercules, CA, USA) microplate reader.
Transfection of DG75 cells: EBNA-2, -3, -5, E346 and control vector Transfection of the EBV-negative BL cell line dG75 with the expression vectors pEBO-EBNA-2, pEBO-EBNA-3 (Kienzle et al., 1996a) , SNOC-EBNA-5 (Sinclair and Farrell, 1992) , pMEP4 (Invitrogen) and pMEP4-EBNA-346 was performed as outlined (Krauer et al., 1996) using electroporation of the plasmid DNA. Surviving cell clones and heterogenous bulk cultures were selected and maintained by 1.2 mg/ml geneticin (GibcoBRL) or 600 mg/ml hygromycin B selection (Roche Boehringer, Mannheim). DG75 pMEP4 and pMEP4-E346 cells were induced with 5 mM cadmium chloride for 16 h.
Plasmid constructs
EBO-EBNA-2: The 10.5 kbp shuttle vector EBO-pLPP (Margolskee et al., 1988) , which contains the oriP/EBNA-1 replicon for episomal maintenance of the vector, the hygromycin resistance gene for eukaryotic selection and an SV40 transcription-cassette was used for constructing a plasmid stably expressing the EBNA-2 ORF of EBV. The B95.8 EBNA-2A gene was restricted with SacI and SalI and subcloned into EBO-pLPP restricted with the same enzyme sites. pMEP4-EBNA346 was generated by insertion of a HindIII restricted fragment containing the genomic region of EBV encoding the EBNA-3 gene family proteins (described in Kienzle et al., 1996b) into pMEP4 restricted with HindIII. The correct orientation and insertion of fragments were all confirmed by DNA sequencing.
Immunoprecipitations
Immunoprecipitations were performed according to a modified method of Harlow and Lane (Antibodies, a Laboratory Manual, 1988) . Briefly, cells were resuspended in RIPA lysis buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF, 10 mg/ml aprotinen, 10 mg/ml leupeptin), incubated on ice for 30 min with occasional mixing and then centrifuged at 10 000 g for 10 min at 41C. The supernatant was precleared with either Protein-A-sepharose or protein-G-sepharose (25/500 ml of supernatant) for 1 h at 41C with constant rocking. Appropriate antibody (3 mg) (anti-chk2 or anti-Sos) was added to 500 ml of supernatant (5 Â 10 6 cells) and the mix was incubated for 2 h at 41C with rocking. A measure of 25 ml of either protein-Asepharose or protein-G-sepharose was added and then incubated for 1 h at 41C with rocking. The samples were then centrifuged at 10 000 g for 1 min, the supernatant discarded and the pellet was washed three times with 1 ml of RIPA buffer containing 1 mM PMSF, 10 mg/ml aprotinen and 10 mg/ml leupeptin. The pellet was resuspended in 25 ml SDS-PAGE loading buffer, heated to 851C for 10 min, centrifuged at 10 000 g for 5 mins, and 10 ml of the supernatant was electrophoresed on polyacrylamide-SDS gels.
Western blotting
Protein extracts from 1 Â 10 6 cells were electrophoresed on 7.5% or 12% SDS polyacrylamide gels (Sambrook et al., 1989) and electrotransfered onto nitrocellulose filters (Hybond-ECL nitrocellulose; Amersham). The membrane was processed as previously described (Krauer et al., 1996) . Expression of the EBNA-1,-2, -3, -4 and -6 proteins was detected by incubation with human serum (MCr serum; Sculley et al. 1984) , diluted 1 : 200 in blotto. The cell cycle proteins were detected by anticdc2 (1 : 500), anti-phosphotyrosine 15 cdc2 (PY15) (1 : 500), anti-cyclin B1 (1 : 500) PCNA (1 : 500), anti-chk2 (1 : 500).
Membranes were washed three times and then incubated in the appropriate peroxidase-conjugated secondary antibody diluted 1 : 1000 in blotto. Following washing, the proteins were visualized using the ECL Western blotting detection system (Amersham, UK). Western blots were scanned using a Molecular Dynamics Laser Densitometer and then analysed using Imagequant software.
DNA cell cycle analysis
For cell cycle analysis, LCLs were grown to log phase and either 100 mg/ml ABHA, 1 mM etoposide or 2 mM HU was added. At 24 and 48 h postaddition, cells were harvested, fixed in 70% ethanol at 01C, and the nuclear DNA was stained using a solution of propidium iodide (50 mg/ml), RNase A (1 mg/ml) and Triton X-100 (0.02%) in PBS. After passing the cells through fine gauge, cell suspensions were analysed on a FACScalibur (Becton Dickinson) using CellQuest and Modfit data analysis software. MPM-2 staining was performed on similar ethanol fixed cells, but in this case cells were incubated with 1 : 200 dilution of MPM-2 antibody for 1 h at room temperature, washed and then incubated with an appropriated FITC-conjugated secondary antibody and propidium iodide and RNase A as above, then washed and processed and analysed by FACS as above.
